Skip to content
Screener

Sarepta Therapeutics, Inc. SRPT Total Liabilities & Equity

Total Liabilities & Equity at other companies

Pfizer logo
PfizerPFE
$207.62B-0.2%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$41.73B+9.2%
BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
$11.72B+57.2%
PTC Therapeutics logo
PTC TherapeuticsPTCT
$2.87B+8.0%
Insmed logo
InsmedINSM
$2.1B-15.2%
Capricor Therapeutics logo
Capricor TherapeuticsCAPR
$326.28M+112%

Other financials

Income statement

See full
Revenue$401.3M-34.3%
Operating income$13.3M-88.5%
Net income-$4.9M-102%
EPS (diluted)-$0.05-103%

Balance sheet

See full
Cash & equivalents$571.1M+11.9%
Total debt$198.2M-7.6%
Total equity$1.5B+8.8%
Total assets$3.2B-13.4%

Cash flow

See full
Operating cash flow-$202.7M+65.3%
CapEx$555.0K-98.3%
Free cash flow-$204.8M+67.3%

Valuation

See full
Market cap$1.77B+1.1%
Enterprise value$1.4B-3.9%
P/S0.9×

Profitability

See full
Operating margin-50.8%-1.6pp
Net margin-6.9%
FCF margin-28.7%-9.2pp

Returns & leverage

See full
Return on equity-9.3%+2,662pp
Debt / equity0.1×0.0×
Current ratio4.4×+1.5×

Where this comes from

Reported directly by Sarepta Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.

The source filing: Sarepta Therapeutics, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:01 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-335003
Line itemAs of June 30, 2026As of December 31, 2025
Preferred stock, $0.0001 par value, 3,333,333 shares authorized; none issued and outstanding
Common stock, $0.0001 par value, 198,000,000 shares authorized; 106,279,142 and 105,623,500 issued and outstanding, respectively, at June 30, 2026 and 105,615,096 and 104,964,220 issued and outstanding, respectively, at December 31, 20251111
Treasury stock, at cost, 655,642 and 650,876 shares at June 30, 2026 and December 31, 2025, respectively(25,263)(25,263)
Additional paid-in capital6,104,5306,042,586
Accumulated other comprehensive (loss) income, net of tax(565)272
Accumulated deficit(4,550,915)(4,876,984)
Total stockholders’ equity1,527,7981,140,622
Total liabilities and stockholders’ equity$3,188,512$3,349,703

Item 1. Financial Statements

FAQ

What is Sarepta Therapeutics, Inc.'s total liabilities & equity?
Sarepta Therapeutics, Inc. (SRPT) reported total liabilities & equity of $3.19B in Q2 2026.
How has Sarepta Therapeutics, Inc.'s total liabilities & equity changed year-over-year?
Sarepta Therapeutics, Inc.'s total liabilities & equity decreased by 13.4% year-over-year, from $3.68B to $3.19B.
What is the long-term trend for Sarepta Therapeutics, Inc.'s total liabilities & equity?
Over 5 years (2020 to 2025), Sarepta Therapeutics, Inc.'s total liabilities & equity has grown at a 2.3% compound annual growth rate (CAGR), from $2.98B to $3.35B.
What does total liabilities & equity mean?
Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.

Ask your AI about Sarepta Therapeutics, Inc.'s total liabilities & equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude